Novo Integrated Sciences Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Novo Integrated Sciences.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Healthcare winstgroei | 20.1% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | None |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch
Jul 11
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump
Apr 18Novo Integrated Sciences prices 4M unit public offering at $.50/unit
Oct 14Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue
Jul 11Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?
Nov 23Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?
Aug 07Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?
Mar 02In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Novo Integrated Sciences onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 5/31/2024 | 14 | -24 | -5 | -5 | N/A |
| 2/29/2024 | 14 | -12 | -5 | -5 | N/A |
| 11/30/2023 | 13 | -14 | -4 | -4 | N/A |
| 8/31/2023 | 13 | -13 | -2 | -2 | N/A |
| 5/31/2023 | 1 | -32 | -1 | -1 | N/A |
| 2/28/2023 | 12 | -35 | -4 | -4 | N/A |
| 11/30/2022 | 12 | -35 | -5 | -5 | N/A |
| 8/31/2022 | 12 | -33 | -6 | -6 | N/A |
| 5/31/2022 | 23 | -12 | -8 | -7 | N/A |
| 2/28/2022 | 11 | -9 | -4 | -4 | N/A |
| 11/30/2021 | 10 | -5 | -2 | -2 | N/A |
| 8/31/2021 | 9 | -4 | -1 | -1 | N/A |
| 5/31/2021 | 8 | -7 | -1 | 0 | N/A |
| 2/28/2021 | 7 | -6 | 0 | 0 | N/A |
| 11/30/2020 | 7 | -6 | 0 | 0 | N/A |
| 8/31/2020 | 8 | -5 | 0 | 0 | N/A |
| 5/31/2020 | 8 | -1 | -1 | -1 | N/A |
| 2/29/2020 | 10 | -1 | -1 | -1 | N/A |
| 11/30/2019 | 10 | 0 | -1 | -1 | N/A |
| 8/31/2019 | 9 | 0 | -1 | -1 | N/A |
| 5/31/2019 | 9 | -1 | -1 | -1 | N/A |
| 2/28/2019 | 9 | -1 | -1 | -1 | N/A |
| 11/30/2018 | 9 | -2 | -1 | -1 | N/A |
| 8/31/2018 | 9 | -2 | -1 | -1 | N/A |
| 5/31/2018 | 9 | -2 | -1 | -1 | N/A |
| 2/28/2018 | 9 | -2 | N/A | -1 | N/A |
| 11/30/2017 | 8 | -1 | N/A | -1 | N/A |
| 8/31/2017 | 8 | -1 | N/A | -1 | N/A |
| 5/31/2017 | 8 | -1 | N/A | -1 | N/A |
| 2/28/2017 | 7 | 0 | N/A | -1 | N/A |
| 11/30/2016 | 7 | 0 | N/A | 0 | N/A |
| 8/31/2016 | 7 | 0 | N/A | 0 | N/A |
| 8/31/2015 | 7 | -2 | N/A | -1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if NVOS's forecast earnings growth is above the savings rate (2.5%).
Winst versus markt: Insufficient data to determine if NVOS's earnings are forecast to grow faster than the US market
Hoge groeiwinsten: Insufficient data to determine if NVOS's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if NVOS's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: Insufficient data to determine if NVOS's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if NVOS's Return on Equity is forecast to be high in 3 years time